Blood Products Advisory Committee; Notice of Meeting, 72834-72835 [2010-29818]

Download as PDF srobinson on DSKHWCL6B1PROD with NOTICES 72834 Federal Register / Vol. 75, No. 227 / Friday, November 26, 2010 / Notices Time: 8:30 a.m. to 5 p.m. Agenda: Presentation and discussion will include recommendations from the Translational Medicine and Therapeutics working group and the Intramural Research Program working group. Any supporting documentation for this meeting, including the agenda, will be available at https:// smrb.od.nih.gov. Sign up for public comment will begin at approximately 7:30 a.m. on December 7 and will be restricted to one sign in per person. In the event that time does not allow for all those interested to present oral comments, anyone may file written comments using the contact person’s address below. Place: National Institutes of Health, Building 31, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892. Contact Person: Lyric Jorgenson, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. smrb@mail.nih.gov. (301) 496–6837. This meeting is being published less than 15 days prior to the meeting due to scheduling conflicts of the Members. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. The meeting will also be Webcast. The draft meeting agenda and other information about the SMRB, including information about access to the Webcast, will be available at https://smrb.od.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: November 19, 2010. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–29748 Filed 11–24–10; 8:45 am] BILLING CODE 4140–01–P VerDate Mar<15>2010 16:32 Nov 24, 2010 Jkt 223001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2010–N–0001] Blood Products Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public. Name of Committee: Blood Products Advisory Committee. General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues. Date and Time: The meeting will be held on December 14, 2010, from 8 a.m. to approximately 5:30 p.m. and on December 15, 2010, from 8 a.m. to approximately 12:45 p.m. Location: Hilton Washington DC/ North, 620 Perry Pkwy., Gaithersburg, MD. Contact Person: Bryan Emery or Pearline Muckelvene, Center for Biologics Evaluation and Research, Food and Drug Administration (HFM– 71), 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area), code 3014519516. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting. Agenda: On December 14, 2010, in the morning, the committee will discuss the risk of dengue virus infection in blood donors. In the afternoon, the committee will discuss murine leukemia virus-related human retroviruses and blood safety. On December 15, 2010, in the morning, the committee will hear updates on the following topics: (1) November 4 and 5, 2010, meeting of the Health and Human Services Advisory Committee on Blood Safety and Availability and (2) December 9 and 10, 2010, FDA workshop entitled ‘‘Product PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 Development Program for Interventions in Patients With Severe Bleeding Due to Trauma and Other Causes,’’ and (3) Research programs in the Laboratories of Hemostasis and Plasma Derivatives, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee link. Procedure: On December 14, from 8 a.m. to 5:30 p.m. the meeting is open to the public. On December 15, from 8 a.m. to 12 noon the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before December 7, 2010. Oral presentations from the public will be scheduled between approximately 10:15 a.m. and 11 a.m. and between 3:45 p.m. and 4:15 p.m. on December 14, 2010, and between approximately 11:30 a.m. and 12 noon on December 15, 2010. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 29, 2010. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 30, 2010. Closed Committee Deliberations: On December 15, from 12 noon to 12:45 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of intramural research programs E:\FR\FM\26NON1.SGM 26NON1 Federal Register / Vol. 75, No. 227 / Friday, November 26, 2010 / Notices and make recommendations regarding personnel staffing decisions. Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Bryan Emery at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: November 19, 2010. Thinh Nguyen, Acting Associate Commissioner for Special Medical Programs. [Docket No. FR–5375–N–46] Federal Property Suitable as Facilities To Assist the Homeless Office of the Assistant Secretary for Community Planning and Development, HUD. ACTION: Notice. AGENCY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless. DATES: Effective Date: November 26, 2010. SUMMARY: FOR FURTHER INFORMATION CONTACT: srobinson on DSKHWCL6B1PROD with NOTICES BILLING CODE 4210–67–P DEPARTMENT OF THE INTERIOR National Park Service [2275–669] Proposed Information Collection; OMB Control Number 1024–0037 National Park Service, Interior. Notice; request for comments. We (National Park Service) will ask the Office of Management and Budget (OMB) to approve the information collection (IC) described below. As required by the Paperwork Reduction Act of 1995 and 5 CFR part 1320, Reporting and Record Keeping Requirements, and as part of our continuing efforts to reduce paperwork and respondent burden, we invite the general public and other Federal agencies to take this opportunity to comment on this information collection. This IC is scheduled to expire on April 30, 2011. We may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. DATES: To ensure we are able to consider your comments on this IC, we must receive them by January 25, 2011. ADDRESSES: Send comments to Daniel Odess, Acting Manager, Archeology Program, National Park Service, 1849 C Street, NW., (2275), Washington, DC 20240. Phone: 202–354–2128; Fax: 202– 371–5102; or by e-mail at mailto:daniel_odess@nps.gov. You may also send comments to Robert Gordon, Information Collection Clearance Officer, National Park Service, 1201 Eye Street NW., (MS 1237), Washington, DC 20005 (mail); or robert_gordon@nps.gov (e-mail). FOR FURTHER INFORMATION CONTACT: To request additional information about SUMMARY: DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT Kathy Ezzell, Department of Housing and Urban Development, 451 Seventh Street, SW., Room 7262, Washington, DC 20410; telephone (202) 708–1234; TTY number for the hearing- and speech-impaired (202) 708–2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 800–927–7588. SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in National Coalition for the Jkt 223001 [FR Doc. 2010–29535 Filed 11–23–10; 8:45 am] ACTION: BILLING CODE 4160–01–P 16:32 Nov 24, 2010 Dated: November 18, 2010. Mark R. Johnston, Deputy Assistant Secretary for Special Needs. AGENCY: [FR Doc. 2010–29818 Filed 11–24–10; 8:45 am] VerDate Mar<15>2010 Homeless v. Veterans Administration, No. 88–2503–OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today’s Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week. PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 72835 this IC, contact David Gadsby, Archeology Program, National Park Service, 1849 C Street, NW., (2275), Washington, DC 20240. Phone: 202– 354–2101; Fax: 202–371–5102; or by email at david_gadsby@nps.gov. You may also contact Robert Gordon by mail or e-mail (see ADDRESSES) or by telephone at 202–354–1936. SUPPLEMENTARY INFORMATION: I. Abstract Section 4 of the Archeological Resources Protection Act (ARPA) of 1979 (16 U.S.C 470cc), and Section 3 of the Antiquities Act (AA) of 1906 (16 U.S.C. 432), authorize any individual or institution to apply to Federal land managing agencies to scientifically excavate or remove archeological resources from public or Indian lands. 43 CFR part 7 for ARPA, and 43 CFR part 3 for the AA, ensure that the resources are scientifically excavated or removed and deposited, along with associated records, in a suitable repository for preservation. Section 13 of ARPA (16 U.S.C. 470ll) requires that the Secretary of the Interior report annually to the Congress on archeological activities conducted pursuant to the Act. The information collected is reported periodically to Congress and is used for land management purposes. The obligation to respond is required to obtain or retain benefits. II. Data OMB Control Number: 1024–0037. Title: Archeology Permits and Reports—43 CFR parts 3 and 7. Service Form Number(s): DI–1926 (permit application) Type of request: Extension of a currently approved information collection. Description of Respondents: Individuals or organizations wishing to excavate or remove archeological resources from public or Indian lands. Respondent’s Obligation: Mandatory. Frequency of Collection: On occasion. Estimated average number of respondents: 736 per year. Estimated average number of responses: 1472 per year (2 per respondent). Estimated average time burden per response: 3 hours. Estimated total annual reporting burden: 2,208 hours. Estimated Annual Nonhour Burden Cost: Not Applicable. III. Comments We invite comments on: • The practical utility of the information being gathered; E:\FR\FM\26NON1.SGM 26NON1

Agencies

[Federal Register Volume 75, Number 227 (Friday, November 26, 2010)]
[Notices]
[Pages 72834-72835]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-29818]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0001]


Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on December 14, 2010, from 
8 a.m. to approximately 5:30 p.m. and on December 15, 2010, from 8 a.m. 
to approximately 12:45 p.m.
    Location: Hilton Washington DC/North, 620 Perry Pkwy., 
Gaithersburg, MD.
    Contact Person: Bryan Emery or Pearline Muckelvene, Center for 
Biologics Evaluation and Research, Food and Drug Administration (HFM-
71), 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA 
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), code 3014519516. Please call the Information 
Line for up-to-date information on this meeting. A notice in the 
Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site and call the appropriate 
advisory committee hot line/phone line to learn about possible 
modifications before coming to the meeting.
    Agenda: On December 14, 2010, in the morning, the committee will 
discuss the risk of dengue virus infection in blood donors. In the 
afternoon, the committee will discuss murine leukemia virus-related 
human retroviruses and blood safety. On December 15, 2010, in the 
morning, the committee will hear updates on the following topics: (1) 
November 4 and 5, 2010, meeting of the Health and Human Services 
Advisory Committee on Blood Safety and Availability and (2) December 9 
and 10, 2010, FDA workshop entitled ``Product Development Program for 
Interventions in Patients With Severe Bleeding Due to Trauma and Other 
Causes,'' and (3) Research programs in the Laboratories of Hemostasis 
and Plasma Derivatives, Division of Hematology, Office of Blood 
Research and Review, Center for Biologics Evaluation and Research.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: On December 14, from 8 a.m. to 5:30 p.m. the meeting is 
open to the public. On December 15, from 8 a.m. to 12 noon the meeting 
is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before December 7, 2010. Oral presentations from the public will be 
scheduled between approximately 10:15 a.m. and 11 a.m. and between 3:45 
p.m. and 4:15 p.m. on December 14, 2010, and between approximately 
11:30 a.m. and 12 noon on December 15, 2010. Those individuals 
interested in making formal oral presentations should notify the 
contact person and submit a brief statement of the general nature of 
the evidence or arguments they wish to present, the names and addresses 
of proposed participants, and an indication of the approximate time 
requested to make their presentation on or before November 29, 2010. 
Time allotted for each presentation may be limited. If the number of 
registrants requesting to speak is greater than can be reasonably 
accommodated during the scheduled open public hearing session, FDA may 
conduct a lottery to determine the speakers for the scheduled open 
public hearing session. The contact person will notify interested 
persons regarding their request to speak by November 30, 2010.
    Closed Committee Deliberations: On December 15, from 12 noon to 
12:45 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of 
intramural research programs

[[Page 72835]]

and make recommendations regarding personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Bryan Emery at least 
7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: November 19, 2010.
Thinh Nguyen,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-29818 Filed 11-24-10; 8:45 am]
BILLING CODE 4160-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.